ArticleNPJ precision oncology2026
Validation of QuANTUM-derived tumor cell fraction for molecular testing in high-grade serous tubo-ovarian carcinoma.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Tumor cell fraction (TCF) estimation is an essential step in homologous recombination deficiency (HRD) testing of tubo-ovarian high-grade serous carcinoma (HGSC). However, it is prone to variability and observer dependence. Here, we assess the reliability of the QuANTUM computational pipeline for TCF estimation (cTCF) in HGSC samples. 70 HGSC cases were retrospectively collected and the AmoyDx HRD Focus Panel was employed for DNA extraction and sequencing. TCF estimates were obtained from multiple pathologists, along with the TCF calculated by the proprietary AmoyDx algorithm. The QuANTUM pipeline-derived cTCF and a manually calculated ground truth (GT) were obtained on the same slides, and concordance analyses were performed. Weighted kappa (Wk) values for the agreement among the various pathologists ranged from 0.28 to 0.63, reflecting low to substantial concordance. The QuANTUM algorithm showed substantial and better agreement with the GT and the AmoyDx tool (Wk = 0.73 and 0.63, respectively) as compared to the pathologists' estimates. No significant differences were observed between QuANTUM, the GT and the AmoyDx tool in identifying cases with tumor cellularity above or below the method-defined 30% cutoff. Considering its high reliability, the QuANTUM algorithm may serve as a robust tool for ensuring adequate TCF evaluation in HGSC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.